EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
COLORADO SPRINGS, Colo., Nov. 07, 2016 -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that company management will be attending three upcoming investor conferences.
On November 16th, 2016, the Company will attend the Stifel Healthcare Conference at the Lotte New York Palace Hotel. The fireside chat will begin at 8:45 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/stifel5/spnc.
On November 17th, 2016, the Company will attend the Canaccord Genuity Medical Technologies & Diagnostics Forum. The fireside chat will begin at 10 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/canaccord24/spnc.
Additionally, on November 30th, 2016, the Company will attend the 28th Annual Piper Jaffray Healthcare Conference. Webcasting details will be available two weeks prior to the event.
Access to each of the three webcasts will also be available in the Events section of the Investor Relations website at http://www.spectranetics.com/investor-relations/investor-events.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen Sr. Director of Finance [email protected] (719) 447-2292 Michaella Gallina Director of Investor Relations [email protected] (719) 447-2417
